An observational study in Surgery of Breast Cancer, sponsored by Institut Paoli-Calmettes. Recruiting at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-05-24.
Sponsored by Institut Paoli-Calmettes · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Breast Neoplasms by Institut Paoli-Calmettes — 6 open to participants now, 10 under way, none of them phase 3. Breast Neoplasms · Institut Paoli-Calmettes.
Among the 24 studies in Breast Neoplasms by Institut Paoli-Calmettes, this one is one of 2 that started in 2006, is one of 5 observational ones, and was the 15th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →6 of the 24 studies in Breast Neoplasms by Institut Paoli-Calmettes are open now, in 1 country. Recruiting first, the newest first:
Institut Paoli-Calmettes · Sites in France
Ages 18+ · Women only
Institut Paoli-Calmettes · Sites in France
Ages 18+ · Healthy volunteers
Institut Paoli-Calmettes · Sites in France
Ages 18+
Institut Paoli-Calmettes · Sites in France
Ages 18+ · Women only
Institut Paoli-Calmettes
Ages 18+
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 7 · Phase 3 3
First in 1995; this study’s year is marked. 2 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50,000 is above the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 72 across the 19 interventional studies, 5,000 across the 5 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Institut Paoli-Calmettes is the lead sponsor of 172 studies on the registry; 50 are open to participants now.
3 of the studies in Breast Neoplasms by Institut Paoli-Calmettes that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05143970Institut Paoli-CalmettesA Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors | 2027-03 |
| NCT05986071Institut Paoli-CalmettesI/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers | 2027-04-01 |
| NCT05519670Institut Paoli-CalmettesA Phase 1b/2 Trial Evaluating Safety and Efficacy of CAPecitabine in Combination With Ni-rapaRIb in HER2-negative Advanced Breast canCEr | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 24 studies in Breast Neoplasms by Institut Paoli-Calmettes, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
For several years, the Paoli-Calmettes Institute has been centralizing the retrospective collection of clinical data of patients operated on for histologically proven breast cancer.
The current cohort (G3S) fed by more than 20 centers has more than 25,000 patient records. The collection centralizes the main characteristics of the patients, the tumor and the treatments. Also included are the date of first recurrence, the localization (local, regional or distant) as well as the death or the date of the latest news. The current database is also updated regularly.
Database of data collection in senological surgery
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
patients operated for histologically proven breast cancer
Procedure: Surgery of breast cancer · Other: Clinical data collection
Surgery of breast cancer
The collection centralizes the main characteristics of the patients, the tumor and the treatments. Also included are the date of first recurrence, the localization (local, regional or distant) as well as the death or the date of the latest news.
follow-up of patients operated for breast cancer
Time frame: 20 years
Plan to share: No
Started Apr 2006 (actual). Primary completion is estimated for Apr 2026, 240 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.